Search results
Does Daytime Hypoglycemia Contribute to Impaired Awareness?
Medscape· 4 days agoIn older adults with T1D, less daytime hypoglycemia was the biggest predictor of improvements in IAH...
Decatur crash with injuries results in driver's arrest on drug charges
Herald & Review· 7 days agoA collision between a motorcycle and a car on North 22nd Street late Friday sent the motorcyclist to...
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
The Kansas City Star· 2 days agoSHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it ...
Why auto insurance premiums will continue rising in 2024
KTVK 3TV Phoenix· 7 days ago2024 Auto Insurance Increases Will Hit You Hard! In 2023, the average price of full-coverage car...
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
Morningstar· 2 days agoSHELTON, CT / ACCESSWIRE / May 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, reports that it ...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 5 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European...
WJTV Jackson· 4 days agoFresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research ...
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
Morningstar· 6 days agoAmgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 5 days ago...20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative colitisa (UC) receiving subcutaneous (SC) TREMFYA® (guselkumab) 200 mg...
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European...
FOX 5 San Diego· 4 days agoFresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research ...